FDA reviewed a specific product for a specific indication. Off-label wellness claims may still be unsupported.
THE EVIDENCE-GRADED DIRECTORY
The Peptide
Atlas.
Know what is medicine, what is research and what is marketing.
A field guide to the peptides most often discussed in metabolic health, recovery, skin, energy, cognition, sexual health and immune care—with evidence limits, risks and linked references.
Explore 31 peptide profiles ↓01 / SEARCH THE COMPLETE ATLAS
Find the signal.
Skip the noise.
Filter every profile by goal and regulatory status, or search a molecule, alias, claim or evidence level. Each result opens a full research passport with evidence limits, risks and source links.Showing 6 of 31 peptide guides
Search by molecule, alias, goal, status or evidence.FDA-approvedHigh for approved indication
Metabolic & fat loss · Wegovy · Ozempic · Rybelsus
Semaglutide
A GLP-1 receptor agonist with strong outcome data for defined metabolic indications.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗FDA-approvedHigh for approved indication
Metabolic & fat loss · Zepbound · Mounjaro
Tirzepatide
A dual GIP/GLP-1 peptide agonist with strong evidence for obesity and type 2 diabetes.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗FDA-approvedHigh for approved indication
Metabolic & fat loss · Saxenda · Victoza
Liraglutide
A daily GLP-1 peptide with established metabolic indications and longer real-world history.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗FDA-approvedHigh for approved indication
Metabolic & fat loss · Egrifta WR · Egrifta SV
Tesamorelin
Approved for excess abdominal fat in adults with HIV lipodystrophy—not general weight loss.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗FDA-approvedHigh for approved indication
Metabolic & fat loss · Imcivree
Setmelanotide
A precision therapy for obesity caused by specific rare genetic pathway disorders.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗InvestigationalEarly human
Metabolic & fat loss · LY3437943 · triple agonist
Retatrutide
A triple GIP/GLP-1/glucagon agonist in clinical development—not an approved drug.INSIDE THE GUIDEWhat it is · What is known · Limits · Next questions
View evidence & safety ↗OUR SCOPE
“Available” does not mean approved—or proven.
This atlas covers peptides commonly marketed in the U.S. biohacking, telehealth, cosmetic and research-chemical ecosystem, plus clinically important approved peptide therapies. It is not every peptide drug used across all of medicine. Regulatory status is current to July 2026 and can change.
HOW TO USE THIS PAGE
Separate approved medicine from promising research and online marketing.
- 01Start with the goal
Choose the clinical or performance question before choosing a molecule.
- 02Check status and evidence
Approval, human evidence, formulation and dose context are separate questions.
- 03Prepare a clinician brief
Bring the exact product, claim, risks, monitoring plan and safer alternatives into the conversation.
0131DETAILED PROFILES
027HEALTH CATEGORIES
0310FDA-APPROVED PEPTIDES*
0416NOT FDA-APPROVED
*Approval applies only to the specific indication, formulation, population and dose described in the prescribing information—not every wellness claim attached to the molecule.
01 / BROWSE BY GOAL
Start with the outcome.
Then check the status.
The same peptide can appear in several marketing categories. We place it where consumers most commonly encounter it and explain the boundaries on its profile.01◇
Metabolic & fat lossIncretins, appetite pathways and body-composition therapies.
702⬡Muscle & recoveryGrowth signaling, tissue repair and performance claims.
703✺Skin & hairCollagen, pigmentation, wound signaling and cosmetic use.
404↑Energy & longevityMitochondrial peptides and healthy-aging claims.
405♥Sexual & reproductiveDesire, reproductive signaling and obstetric hormones.
306◎Cognition & sleepNeuroactive peptides marketed for focus, anxiety and sleep.
307✦Immune & gutImmune signaling, inflammation and barrier-health claims.
3STATUS KEY
Four labels that change the entire conversation.
Legitimate access may be limited to registered clinical trials.
Topical or oral consumer use does not establish injectable safety.
Being sold online or compounded does not make a product approved.
02 / READ THE RESEARCH
A promising mechanism is not a proven outcome.
Our evidence labels follow the drug-development path: laboratory signals can justify human research, but only well-designed clinical studies can establish benefits, harms and a usable dose.Useful for mechanism and toxicity questions. It cannot establish a consumer treatment.
Usually explores safety, pharmacology and dose—not whether a wellness claim works.
Tests the intervention in people with the target condition and continues safety work.
Larger studies test whether benefits hold up against a comparator and reveal more harms.
Review applies to a defined product, indication and label; monitoring continues after launch.
04 / REAL-WORLD CHECKS
Research does not end at the molecule.
Product identity, pharmacy legitimacy, sport rules and adverse-event reporting can matter as much as the headline claim.VERIFYCheck an online pharmacy.
Use FDA’s BeSafeRx tools before purchasing prescription medicine online.
Open FDA BeSafeRx ↗ATHLETESCheck sport status.Many peptide hormones, growth factors and related substances are prohibited. Search the exact active ingredient and confirm with your governing body.
Open Global DRO ↗REPORTDocument a serious problem.FDA MedWatch accepts reports about serious reactions, product-quality problems, use errors and therapeutic failures.
Open FDA MedWatch ↗Competitive-sport rules change and can be substance-, route- and timing-specific. The 2026 WADA Prohibited List is in force; Global DRO is a medication-status reference, not a substitute for your anti-doping organization.
BEFORE ANY PEPTIDE
Verify five things before a needle ever enters the conversation.
- 01Exact identity
Brand, molecule, salt or analog, concentration, route and lot.
- 02Regulatory status
Approved product, lawful compounding need, clinical trial or gray market.
- 03Human evidence
Meaningful outcomes in people—not only animal mechanisms or testimonials.
- 04Clinical fit
Diagnosis, contraindications, medication interactions and monitoring plan.
- 05Exit criteria
What success means, when to reassess and which symptoms mean stop.
THE MODERN BIO STANDARD